The optimal anesthetic for electroconvulsive therapy (ECT) is a frequently studied but unresolved issue. Methohexital and propofol are 2 widely used anesthetic agents for ECT. The purpose of this study was to determine which of the 2 agents was associated with superior clinical outcomes.
Records from all patients who had undergone separate ECT courses with methohexital and propofol between 1992 and 2008 (n = 48) were reviewed for a retrospective within-subject comparison of outcome measures. The clinical outcomes we examined were number of treatments required in a course of ECT, changes in the Montgomery-Åsberg Depression Rating Scale and Mini Mental Status Examination, and length of stay in the hospital after initiation of ECT. Additionally, we compared treatment delivery between methohexital and propofol treatment courses, measuring rate of restimulation for brief seizures, seizure duration, percentage of treatments that were bilateral, and average charge administered.
Data from 1314 treatments over 155 ECT courses were reviewed. Improvement in depressive symptoms, based on the Montgomery-Åsberg Depression Rating Scale, was not affected by choice of anesthetic agent. However, when right unilateral electrode placement was used, patients receiving propofol required significantly more treatments than those receiving methohexital. Propofol was also associated with a significantly higher requirement for bilateral ECT and higher stimulus dosing. Seizure duration was significantly shorter in the propofol condition, with more patients requiring restimulation for brief seizures. Length of stay in the hospital and cognitive outcomes were not significantly different between propofol and methohexital treatments.
We recommend methohexital as the induction agent of choice for ECT, especially with right unilateral placement.
From the *Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, †Johns Hopkins University and ‡Department of Neuroscience, Johns Hopkins University, Baltimore, MD.
Received for publication March 15, 2011; accepted June 21, 2011.
Reprints: Punit V. Vaidya, MD, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, 600 N. Wolfe St., Meyer 3-181, Baltimore, MD 21287 (e-mail: email@example.com).
Drs. Vaidya and Anderson contributed equally to the study.
No financial support was provided for this study.
Drs. Vaidya and Reti receive research support for clinical trials from Brainsway Inc. and Neuronetics Inc. Dr. Jayaram is on an advisory board for Janssen. Dr. Anderson, Mr. Bobb, and Ms. Pulia declare no conflicts of interest.